Sign in
Not yet taking people in United StatesPhase 1

BMS-986553 for Adults With Autoimmune Diseases That Have Not Responded to Treatment

Tests the safety of BMS-986553 in adults with hard-to-treat autoimmune diseases.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Ann Arbor, Great Neck, Morristown, Newport Beach, Omaha, Philadelphia, Saint Paul, Salt Lake City, Seattle, and Worcester, United StatesSee the 11 sitesAlso in 5 other countries, 12 sites
Trial code
Registry title
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Status
Not yet recruiting
Phase
Phase 1
People taking part
60 people, planned
Started
30 Oct 2026
Expected to end
31 Jan 2033
Type of study
Interventional
Treatments tested
  • BMS-986553
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a hard-to-treat autoimmune disease: lupus (SLE), inflammatory muscle disease (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA) or Sjögren's disease (SjD).

Age
18 years or older
Sex
All sexes can join.
Disease stage
A confirmed diagnosis of SLE, IIM, SSc, RA or primary SjD that meets the named ACR/EULAR classification criteria. The study title calls the diseases refractory (not responding to treatment).

Main reasons for not taking part

  • Having other systemic immune disorders
  • Healthy volunteers cannot join

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • SLE participants: Must have diagnosis of SLE defined as fulfilling the 2019 ACR/EULAR classification criteria of SLE
  • IIM participants: Must have diagnosis of IIM defined as fulfilling the 2017 ACR/EULAR classification criteria for probable or definite IIM
  • SSc participants: Must have diagnosis of SSc defined as fulfilling 2013 ACR/EULAR classification criteria for SSc
  • RA participants: Must have diagnosis of RA, defined as fulfilling 2010 ACR/EULAR criteria for RA
  • Primary SjD Participants: Must have diagnosis fulfilling the 2016 ACR/EULAR Classification Criteria

Who cannot take part

  • Participants must not have other systemic immune disorders. Other protocol-defined Inclusion/Exclusion criteria apply

Where in United States

Also in 5 other countries, 12 sites

  • Ann Arbor, MichiganHospital not named in the registryContact: Site 0004Not yet recruiting
  • Great Neck, New YorkHospital not named in the registryContact: Site 0052Not yet recruiting
  • Morristown, New JerseyHospital not named in the registryContact: Site 0007Not yet recruiting
  • Newport Beach, CaliforniaHospital not named in the registryContact: Site 0064Not yet recruiting
  • Omaha, NebraskaHospital not named in the registryContact: Site 0062Not yet recruiting
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Site 0008Not yet recruiting
  • Saint Paul, MinnesotaHospital not named in the registryContact: Site 0013Not yet recruiting
  • Salt Lake City, UtahHospital not named in the registryContact: Site 0015Not yet recruiting
  • Seattle, WashingtonHospital not named in the registryContact: Site 0005Not yet recruiting
  • Seattle, WashingtonHospital not named in the registryContact: Site 0003Not yet recruiting
  • Worcester, MassachusettsHospital not named in the registryContact: Site 0001Not yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).

The group in the trial

  • BMS-986553Treatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases
Plain-language title
BMS-986553 for Adults With Autoimmune Diseases That Have Not Responded to TreatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 October 2026